National Bank of Canada’s Beam Therapeutics BEAM Stock Holding History

National Bank of Canada’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.08K	Hold	213	–	–	﹤0.01%	2459
2025 Q4	$5.9K	Buy	213 +40	+23%	+$1.02K	﹤0.01%	2408
2025 Q3	$4.2K	Buy	+173	New	+$3.44K	﹤0.01%	2481
2024 Q3	–	Sell	-3,000	Closed	-$69.2K	–	2774
2024 Q2	$69.2K	Buy	3,000 +2,000	+200%	+$49.1K	﹤0.01%	1590
2024 Q1	$21.3K	Sell	1,000 -500	-33%	-$15.6K	﹤0.01%	2013
2023 Q4	$41K	Buy	1,500 +1,000	+200%	+$24.8K	﹤0.01%	1828
2023 Q3	$10.6K	Buy	+500	New	+$13.4K	﹤0.01%	2184
2023 Q1	–	Sell	-600	Closed	-$23.5K	–	2713
2022 Q4	$23.5K	Buy	600 +200	+50%	+$8.96K	﹤0.01%	1968
2022 Q3	$19K	Sell	400 -200	-33%	-$11.4K	﹤0.01%	2019
2022 Q2	$23K	Buy	+600	New	+$23.9K	﹤0.01%	2026

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

National Bank of Canada's BEAM Position: Q1 2026 in Review

National Bank of Canada held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 213 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

National Bank of Canada first reported a position in BEAM in Q2 2022 and has held it in 10 quarters since. The position peaked at $69.2K in Q2 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

National Bank of Canada held 213 shares of Beam Therapeutics worth $5.08K as of Q1 2026.
National Bank of Canada left its Beam Therapeutics share count unchanged in Q1 2026.
Beam Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2459 holding.
National Bank of Canada first reported a position in Beam Therapeutics in Q2 2022 and has held it in 10 quarters since.
National Bank of Canada's Beam Therapeutics position peaked at $69.2K in Q2 2024.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.